产品名称：赖诺普利二水物

产品别名：**Lisinopril dihydrate**；赖诺普利二水合物；**MK-521 dihydrate**

<table>
<tr><td colspan="2">生物活性：</td></tr>
<tr><td>Description</td><td>Lisinopri (dihydrate) (IMK-521 (dihydrate)) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks. .</td></tr>
<tr><td>IC₅₀ & Target</td><td>ACE.</td></tr>
<tr><td>In Vitro</td><td>Lisinopri (dihydrate) (IMK-521 (dihydrate)) is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy[1][2].</td></tr>
<tr><td>Solvent&Solubility</td><td>
In Vitro:
H₂O : 20 mg/mL (45.30 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
<table>
<tr><td rowspan="4">Preparing Stock Solutions</td><td>Solvent / Mass / Concentration</td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr>
<tr><td>1 mM</td><td>2.2649 mL</td><td>11.3245 mL</td><td>22.6490 mL</td></tr>
<tr><td>5 mM</td><td>0.4530 mL</td><td>2.2649 mL</td><td>4.5298 mL</td></tr>
<tr><td>10 mM</td><td>0.2265 mL</td><td>1.1325 mL</td><td>2.2649 mL</td></tr>
</table>
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
</td></tr>
<tr><td>References</td><td>[1]. Andujar-Sanchez, M., V. Jara-Perez, and A. Camara-Artigas, Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett, 2007. 581(18): p. 3449-54.
[2]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24.</td></tr>
</table>